CureVac N.V. logo
CureVac N.V. CVAC

Quarterly report 2022-Q2
added 08-18-2022

report update icon

CureVac N.V. Cost of Revenue 2011-2026 | CVAC

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue CureVac N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
238 M 14.2 M 28 M 17.7 M - - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
238 M 14.2 M 74.5 M

Quarterly Cost of Revenue CureVac N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - 37.2 M - - - 15.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum Minimum Average
37.2 M 15.8 M 26.5 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
369 K - -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
Aptorum Group Limited Aptorum Group Limited
APM
421 K $ 0.88 -2.07 % $ 6.47 M chinaChina
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
81.8 M $ 22.67 1.66 % $ 3.76 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
145 M - 1.93 % $ 17.4 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
90 K - 5.93 % $ 314 M canadaCanada
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
602 K - - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
2.91 B $ 102.06 - $ 27.2 B germanyGermany
BioDelivery Sciences International BioDelivery Sciences International
BDSI
23.4 M - -4.8 % $ 255 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
18.6 M $ 4.09 -0.24 % $ 437 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
36.7 M $ 23.29 -0.56 % $ 2.96 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
96.4 M $ 1.48 4.23 % $ 394 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
12.4 B - - $ 96.9 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
70.7 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Evogene Ltd. Evogene Ltd.
EVGN
767 K $ 0.79 1.28 % $ 27.9 M israelIsrael
bluebird bio bluebird bio
BLUE
33.5 M - - $ 546 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
12.6 M - - $ 35.4 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
164 K $ 1.06 -2.75 % $ 12.9 M usaUSA